PR Newswire Asia's news > Biotechnology

 < Previous page   |   Detail   |   Print    Next page > 
     
CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
2026-07-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Telix H1 2026 Results: Investor Webcast Notification
2026-07-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates
2026-07-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science
2026-07-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Continuity Biosciences Appoints Vicky Papoutsis to Board of Directors
2026-07-30T    Biotechnology   Health Care/Hospital 
NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
2026-07-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Propel Health Australia Highlights Emerging Research into Fulvic Acid and Microplastics
2026-07-30T    Biotechnology   Health Care/Hospital 
Piramal Pharma Limited Announces Results for Q1 FY27
2026-07-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms
2026-07-29T    Banking/Financial Service   Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
2026-07-29T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.